Day One Biopharmaceuticals Q1 2024 Earnings Report $7.93 -0.14 (-1.73%) As of 03/31/2025 04:00 PM Eastern Earnings HistoryForecast Day One Biopharmaceuticals EPS ResultsActual EPS-$0.72Consensus EPS -$0.67Beat/MissMissed by -$0.05One Year Ago EPSN/ADay One Biopharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ADay One Biopharmaceuticals Announcement DetailsQuarterQ1 2024Date5/6/2024TimeN/AConference Call ResourcesPress ReleaseDAWN Earnings HistoryPowered by Remove Ads Day One Biopharmaceuticals Earnings HeadlinesThe Goldman Sachs Group Has Lowered Expectations for Day One Biopharmaceuticals (NASDAQ:DAWN) Stock PriceMarch 27, 2025 | americanbankingnews.comDay One Biopharmaceuticals price target lowered to $34 from $39 at JPMorganMarch 5, 2025 | markets.businessinsider.comElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believes will be Elon’s greatest invention ever… Yes, even bigger than Tesla or SpaceX.April 1, 2025 | Brownstone Research (Ad)Day One Biopharmaceuticals, Inc. (DAWN): A Bull Case TheoryMarch 5, 2025 | msn.comOppenheimer Sticks to Their Hold Rating for Day One Biopharmaceuticals (DAWN)February 27, 2025 | markets.businessinsider.comDay One price target lowered to $30 from $34 at JonesResearchFebruary 27, 2025 | markets.businessinsider.comSee More Day One Biopharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Day One Biopharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Day One Biopharmaceuticals and other key companies, straight to your email. Email Address About Day One BiopharmaceuticalsDay One Biopharmaceuticals (NASDAQ:DAWN), a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.View Day One Biopharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio? Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
